Clinical Trials Browser

VEXAS syndrome, Autoimmune Diseases, Hematologic Diseases, Immune System Diseases, Inflammation, Leukemia, Lymphoma, Lymphoproliferative Disorders, Monoclonal Gammopathy of Undetermined Significance, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Juvenile, Myelodysplastic-Myeloproliferative Diseases

NCT07391046 2026-02-05

AMBU-VAX

Not yet recruiting

1,500 enrolled

Frailty, Autoimmune Diseases, Chronic Disease, Neoplasms, Inflammatory Bowel Diseases, HIV Infections, Renal Insufficiency, Chronic

NCT06827587 2025-02-14

Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis

Phase NA Not yet recruiting

60 enrolled

Autoimmune Diseases, Myasthenia Gravis, Neuromuscular Diseases

NCT06723548 2024-12-09

Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis

Phase 4 Not yet recruiting

30 enrolled

Autoimmune Diseases, Myasthenia Gravis

NCT06567080 2024-08-22

JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases

Phase 1 Not yet recruiting

15 enrolled

Autoimmune Diseases, Lupus Erythematosus, Systemic

NCT06507800 2024-07-18

CATCH CANCER

Not yet recruiting

500 enrolled

Autoimmune Diseases, Neoplasms

NCT06416267 2024-05-16

MBL RiskConseq

Not yet recruiting

1,500 enrolled

LymphoidOther hematologic neoplasm

Alzheimer Disease, Autoimmune Diseases, Cardiovascular Diseases, Dementia, Infections, Neoplasms, Parkinson Disease, Leukemia, Lymphocytic, Chronic, B-Cell

Clinical Trials

CHIS

AMBU-VAX

Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis

Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis

JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases

CATCH CANCER

MBL RiskConseq